Annunziata S*, Laudicella R, Caobelli F, Pizzuto DA and Young AIMN Working Group Pages 1 - 8 ( 8 )
Background. 18F-FDG PET/CT has been suggested as an effective tool to stage patients affected by melanoma. In the latest years, new radiopharmaceuticals have been proposed and the use of hybrid PET/ceCT has emerged.
Objective. To review recent evidence on the role of PET/CT in melanoma staging as well as its potential for future developments.
Methods. A comprehensive computer literature search of PubMed/MEDLINE was carried out to find relevant published articles concerning the feasibility of PET/CT in patients with malignant melanoma.
Results. Some recent studies about potentials and limitation of 18F-FDG PET/CT in staging melanoma, new PET radiotracers beyond 18F-FDG and application of hybrid PET/ceCT have been reviewed and discussed.
Conclusion. PET/CT plays an important role in the staging workup of patients affected by melanoma. New radiopharmaceuticals and hybrid PET/ceCT could improve the potential of this diagnostic tool in this field.
Melanoma , PET/CT, radiopharmaceuticals, Fluorodeoxyglucose, PET, computed tomography , metastases
Institute of Nuclear Medicine, Università Cattolica del Sacro Cuore, Rome, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, Nuclear Medicine Unit, University of Messina, Department of Nuclear Medicine, Clinic of Radiology and Nuclear Medicine, University Hospital Basel. Basel, Department of Nuclear Medicine, University Hospital Zurich/University of Zurich. Raemistrasse 100, 8091 Zurich, Executive Committee of the Italian Association of Nuclear Medicine, Milan